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Abstract: This study used a rat subcutaneous implantation
model to investigate gradual in situ pore formation in a
self-regulating degradable chitosan-based material, which
comprises lysozyme incorporated into biomimetic calcium
phosphate (CaP) coatings at the surface to control the scaffold
degradation and subsequent pore formation. Speciﬁcally, the
in vivo degradation of the scaffolds, the in situ pore formation,
and the tissue response were investigated. Chitosan or
chitosan/starch scaffolds were studied with and without a CaP
coating in the presence or absence of lysozyme for a total of
six experimental groups. Twenty-four scaffolds per group
were implanted, and eight scaffolds were retrieved at each of
three time points (3, 6, and 12 weeks). Harvested samples were
analyzed for weight loss, microcomputed tomography, and
histological analysis. All scaffolds showed pronounced weight
loss and pore formation as a function of time. The highest
weight loss was 29.8% 6 1.5%, obtained at week 12 for CaP
chitosan/starch scaffolds with lysozyme incorporated. Moreover,
all experimental groups showed a signiﬁcant increase in poros-
ity after 12 weeks. At all time points no adverse tissue reaction
was observed, and as degradation increased, histological
analysis showed cellular ingrowth throughout the implants.
Using this innovative methodology, the ability to gradually gen-
erate pores in situ was clearly demonstrated in vivo. VC 2011 Wiley
Periodicals, Inc. J Biomed Mater Res Part A: 00A: 000–000, 2011.
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INTRODUCTION
The evaluation of a bone tissue engineering constructs in an
in vivo subcutaneous model is often the ﬁrst step following
in vitro characterization. In previous studies we proposed
the use of nonporous, stimulus responsive chitosan-based
scaffolds with self-regulated degradation for bone tissue
engineering applications.1,2 This approach is based on the
use of a material that exhibits both self-regulated degrada-
tion and the ability for gradual in situ pore formation. Chito-
san and starch by themselves or in combination do not have
adequate bone bonding, osteoconductive or osteoinductive
properties for bone tissue engineering applications, and
calcium phosphate (CaP) coating may give rise to such key
properties.
The incorporation of lysozyme into CaP coatings
prepared at the surface of chitosan-based scaffolds using a
biomimetic methodology was used previously to control and
tailor the degradation rate of scaffolds and subsequent for-
mation of pores.2–4 The main advantage of the biomimetic
method5–7 is the use of physiological conditions (pH 7.4
at 37C) that simulate those involved in the formation of
apatite in bone.8 Moreover, this technique allows the
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incorporation of proteins and bioactive agents into CaP
coatings without compromising their activity.2,9,10 In vitro,
these scaffolds gradually exhibit in situ pore formation.2 To
prove the concept of in situ pore formation in vitro, previ-
ous studies simulating the inﬂammatory response were
performed, and the formation of pores was clearly visible
when lysozyme was incorporated in CaP chitosan scaffolds.2
The combination of chitosan with other biodegradable mate-
rials has already been shown to be effective for bone-
related applications.11–13 The inclusion of starch in chitosan
matrices constitutes an interesting approach towards
obtaining scaffolds with enhanced degradation rates since
starch is acting as a sacriﬁce material.1 Furthermore, starch
is enzymatically hydrolyzed by a-amylase, an enzyme pres-
ent in blood serum. Several in vitro and in vivo studies have
shown that scaffolds produced from starch-based biomateri-
als are biocompatible in speciﬁc applications14–16 and bio-
degradable in different conditions.1,3,17,18
To prove the concept of in situ pore formation within
chitosan-based scaffolds in vivo, a rat subcutaneous implan-
tation model was used. It was hypothesized that using this
innovative methodology, the scaffolds, which at the time of
implantation exhibit very promising mechanical properties
due to the absence of macroporosity,1 will exhibit in situ
pore formation facilitated by previously impregnated
lysozyme and by enzymes present in the body (namely the
a-amylase and lysozyme). This study was designed to inves-
tigate the following speciﬁc aims: (i) study the host tissue
response (ii) assess the degradation of the scaffolds in vivo,
(iii) characterize the in situ formation of pores, and (iv)
assess in vivo the concept of in situ pore formation.
MATERIALS AND METHODS
Materials
Degradable scaffolds based on chitosan and corn starch
were used. Two different compositions were prepared using
a precipitation method: chitosan (CH) and chitosan/starch
scaffolds (CS).1 Brieﬂy, chitosan was dissolved in 1% (v/v)
acetic acid to obtain a 5% (w/v) solution. Then, using the
same procedure, another formulation was prepared with the
following ratio: 60/40 chitosan/starch. The chitosan and
chitosan/starch solutions were cast into moulds and frozen
(20C) overnight.1 They were then immersed in a precipi-
tation solution (25% (v) NaOH 1M and 75% (v) Na2SO4
0.5M)1,19 and washed several times with distilled water.
After this procedure, four other formulations were prepared
based on previously used biomimetic coating techniques2–4
consisting of an impregnation of the materials with bioac-
tive glass called Bioglass( (45S5; NOVABONE Alachua, FL)
followed by an immersion in a 1 simulated body ﬂuid
(SBF, 37C, pH 7.4) solution, which ionic concentrations are
similar to those of the human blood plasma. Brieﬂy, chito-
san (CH) and chitosan/starch (CS) scaffolds were immersed
in a wet bed of bioglass for 6 h on an orbital rotator. After
that, the scaffolds where immersed in 1 SBF with and
without lysozyme (1 g/L) for 7 days at 37C (nucleation
stage). This stage allows for the formation of CaP nuclei.
After the nucleation stage, all samples were washed with
distilled water and immersed in 1.5 SBF solution for
7 days at 37C to enhance CaP nuclei growth (growth stage).
Four different samples were obtained using the biomimetic
coating technique: CaP chitosan scaffolds (CaPCH), CaP chito-
san/starch scaffolds (CaPCS), CaP chitosan scaffolds with
incorporated lysozyme (CaPCH þ lysozyme), and CaP chito-
san/starch scaffolds with incorporated lysozyme (CaPCS þ
lysozyme).2–4 Thus, a total of six scaffold compositions were
prepared: CH, CS, CaPCH, CaPCS, CaPCH þ lysozyme, and
CaPCS þ lysozyme. All chemical reagents were purchased from
Sigma (St. Louis, MO) unless otherwise speciﬁed.
Implants preparation
In this study, 5 mm diameter and approximately 1.5 mm
thick scaffolds were used. All scaffolds were sterilized with
ethylene oxide gas for 14 h prior to implantation in condi-
tions described elsewhere.20,21 One day before subcutane-
ous implantation surgery, the implants were prewetted with
phosphate buffered saline (PBS) solution in 24-well plates
overnight under sterile conditions.
Subcutaneous implantation
All animal manipulations were approved by Rice University’s
Institutional Animal Care and Use Committee. Twenty-four
male Wistar rats 4144 days old (Charles River Laboratories,
USA) were used for subcutaneous implantation of acellular
scaffolds. Three implantation periods were used: 3, 6, and
12 weeks (3W, 6W, and 12W, respectively). Anesthesia was
induced with a 4% isoﬂurane/oxygen mixture and main-
tained with 2% isoﬂurane during surgical manipulation. The
rats were monitored to ensure that an appropriate surgical
plane of anesthesia was maintained. The fur on the dorsum of
the rat was clipped closely prior to surgery. Then, the animals
were placed in a ventral position, the clipped dorsum was
disinfected with povidone-iodine, and six small longitudinal
incisions were made. A pocket was bluntly dissected at each
incision, and one scaffold was placed in each pocket. One
implant from each experimental group was implanted in
24 rats (six implants per rat). A total of eight scaffolds per
experimental group per time point were implanted. Previous
studies reported successful implantation of six materials in
rat dorsal subcutaneous pockets using Wistar rats of similar
or lower size.22–25 The incisions were closed with simple
interrupted 5-0 Vicryl sutures. Each animal received an intra-
peritoneal injection of sterile saline to aid postoperative
recovery (1 mL/100 g/h of anesthesia) and a subcutaneous
injection of buprenorphine (0.025 mg/kg) both before and
8–12 h after surgery for analgesia. On the following day,
two additional doses of subcutaneous buprenorphine
(0.025 mg/kg) were injected for continued postoperative
analgesia regimen (i.e., at 20–24 and 32–36 h postop). Care
was taken to give all subcutaneous injections caudal to the
implantation sites. Animals were housed individually with
water and food given ad libitum. At each time point, animals
were anesthetized by isoﬂurane inhalation and euthanized
with carbon dioxide asphyxiation. The implants were
retrieved after a bilateral thoracotomy was performed to
ensure death.
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Preparation of samples for weight loss and
microcomputed tomography analysis
After each implantation time, three scaffolds from each
group were decellularized prior to weight loss measurement
and microcomputed tomography (l-CT) analysis. Brieﬂy, the
scaffolds were immersed in double-distilled water (ddH2O)
and placed in a 24-well plate at 20C. After that, scaffolds
underwent three freeze/thaw cycles in liquid nitrogen and
in a 37C water bath, respectively, to disrupt attached
cells and remove cellular debris.26 Finally, scaffolds were
air-dried in a laminar ﬂow hood.
Weight loss measurements
All samples were weighed before subcutaneous implantation
(initial weight). After 3, 6, and 12 weeks of implantation,
three decellularized samples of each condition were dried
and weighed to determine the ﬁnal weight and calculate the
weight loss in Eq. (1).
Weight loss ð%Þ ¼ Initial weight  Finalweight
Initial weight
(1)
Microcomputed tomography analysis
Retrieved implants used for weight loss measurements were
also used for l-CT analysis. Three samples from each group
were used as controls (i.e., nonimplanted specimens). l-CT
was carried out with a high-resolution l-CT scanner (Sky-
scan 1072, Skyscan, Kontich, Belgium) using a pixel size of
5.27 lm and integration time of 1.7 ms. The X-ray source
was set at 70 keV of energy and 142 lA of current. Approxi-
mately 400 projections were acquired over a rotation range
of 180 with a rotation step of 0.45. Data sets were
reconstructed using standardized cone-beam reconstruction
software (NRecon v1.4.3, SkyScan). The output format for
each sample was 400 serial 1024  1024 bitmap images.
Representative data sets were segmented into binary images
using a dynamic threshold of 40–255 for polymer and 130–
255 for CaP coating (gray values). These representative data
sets were used for morphometric 3D analysis (CT Analyser,
v1.5.1.5, SkyScan) and to build 3D models (ANT 3D creator,
v2.4, SkyScan). The morphometric analysis included poros-
ity and pore interconnectivity. 3D virtual models of repre-
sentative regions in the bulk of the scaffolds were created,
visualized, and registered using image processing software
(CT Analyser and ANT 3D creator).
Thermogravimetric analysis
The same samples of different conditions used for weight
loss measurements and l-CT analysis were used for ther-
mogravimetric analysis (TGA). The amount of inorganic
component (mineral) was estimated by TGA as a function of
implantation time. TGA was performed using a TGA Q 500
series thermogravimetric analyser (TA Instruments, USA), at
a heating rate of 10C/min, under a nitrogen ﬂow of 40 ml/
min and for a temperature range from 50 to 450C. Three
samples (approx. 10 mg) of each material were tested both
before and after implantation (3, 6, and 12 weeks).
A typical thermogram showed two main plateaus; the
ﬁrst corresponds to the complete evaporation of sample
moisture, and the second, to the end of organic fraction
thermal degradation. We considered two temperature points
(150 and 450C) at the ﬁrst derivative local minimum, one
from each plateau. These temperature points were used to
estimate the weight fractions of organic (chitosan or/and
starch) and inorganic (mineral) components: the weight
measured at 150C corresponds to the sample dry weight,
and the weight at 450C includes both inorganic compo-
nents and ashes resulting from the organic component
pyrolysis.
Histology
After euthanasia, the implants were retrieved along with the
surrounding tissue and processed for histology. Five speci-
mens from each group per time point were ﬁxed in 10%
neutral buffered formalin and then dehydrated in a graded
series of ethanol, immersed in inﬁltration solutions, embed-
ded in Technovit glycol methacrylate (kit 8100, Heraeus
Kulzer, EBSciences, USA) and subsequently polymerized.
Three specimens from each group per time period were cut
to obtain longitudinal sections, and two specimens were cut
to obtain transverse sections of 7 lm thickness using a
modiﬁed microtome equipped with a tungsten blade (Leica
RM 2155).
Sections were stained with hematoxylin and eosin (H&E)
to evaluate the in vivo degradation, pore formation, cellular
inﬁltration throughout the implants and tissue response.
The van Gieson stain, which presents an afﬁnity for col-
lagen, was also used. In this case, collagen stains pinkish-
red, cells brownish, and muscle stains yellow. The sections
were subsequently examined under polarized light to visual-
ize mature collagen.
For visualization of the CaP coating, additional sections
were exposed to 5% silver nitrate solution under UV for
25 min and counterstained with 0.5% safranin O solution. All
images were obtained using an Olympus BX61 Motorized
System Microscope and attached video camera (Olympus
DP70). Histological sections from all time points were scored
by the authors (AMM, ARP, and CMA), blinded for group con-
ditions and implantation time, and consensus was reached on
the ﬁnal score. The cellular ingrowth within the implants and
the degradation of each sample was qualitatively scored
based on dissolution, cracks, and fragmentation on a scale
modiﬁed from De Jong, as shown in Table I.27
Immunohistochemistry
Further, immunohistochemical staining was performed to
detect a-smooth muscle actin (a-SMA). The antibody against
a-SMA (Abcam, ab5694) was used to detect blood vessels
since a-SMA is one of the constituents of the vessel walls,
allowing the observation of vessel ingrowth. The slides were
washed with phosphate buffered saline and endogenous
peroxidase was blocked with 0.6% hydrogen peroxide
(H2O2) in methanol, at room temperature (RT) for 30 min.
R.T.U. VectastainV
R
Universal Elite ABC Kit (Vector, VCPK-
7200) was used for antibody incubation, according to the
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instructions of the manufacturer. Brieﬂy, sections were incu-
bated overnight with the primary antibody (anti-a-SMA) at
4C and humidiﬁed atmosphere. After washing with PBS
solution, antibody detection was revealed by using the
Peroxidase Substrate Kit DAB (Vector, VCSK-4100). Slides
were washed in water for 5 min and then counterstained
with Harris’ hematoxylin for nuclear contrast, at RT for
2 min. After this, samples were washed with water, dehy-
drated in graded ethanol (50, 70, 95, and 100%), cleared
with xylene, and mounted with Histoﬂuid mounting medium
(Marienfeld, Germany). All images were obtained using an
Olympus BX61 Motorized System Microscope and attached
video camera (Olympus DP70).
Statistics
Results of weight loss and l-CT analysis are expressed as
means 6 standard deviation with n ¼ 3 for each group.
Results of histological scoring are expressed as means 6
standard deviation with n ¼ 5 for each group. Single factor
analysis of variance (ANOVA) was used to determine statis-
tical signiﬁcance within a data set. If ANOVA detected a
signiﬁcant difference within the data set, Tukey’s honestly
signiﬁcantly different (HSD) multiple comparison test was
used to determine signiﬁcant differences between groups
and conditions. All tests were conducted with a conﬁdence
interval of 95% (p < 0.05).
RESULTS AND DISCUSSION
Weight loss measurements
Lysozyme, an enzyme ubiquitous in the human body,28,29
has been reported to be responsible for the in vivo degrada-
tion of chitosan30,31 and has been previously incorporated
into and released from CaP coatings of chitosan-based scaf-
folds, while retaining biological activity.2,3 As observed in
Figure 1, all groups degraded gradually as a function of
implantation time. A signiﬁcant increase (p < 0.05) in weight
loss was observed after 3, 6, and 12 weeks for chitosan scaf-
folds in the presence of lysozyme (CaPCHþlysozyme), as
compared to chitosan scaffolds (CH) at the respective time
points (Fig. 1). These results indicate that lysozyme has a sig-
niﬁcant effect in the biodegradation of chitosan. Statistically
signiﬁcant weight loss (p < 0.05) was observed for chitosan/
starch scaffolds (CS) with and without CaP coating and both
in the presence and in the absence of lysozyme (CaPCS þ
lysozyme and CaPCS, respectively) after 12 weeks of
implantation. The highest weight loss after 12 weeks was
29.8% 6 1.5% for CaP chitosan/starch scaffolds with
lysozyme incorporated (Fig. 1). It is expected that for longer
TABLE I. Histological Grading Scale for the Degradation and Cellular Growth Within the Implants
Scoring Category Response Score
Cellular growth within
implant
Abundance presence of cells and ﬁbrous tissue around all fragments 4
Marked presence of cells and/or formation of ﬁbrous tissue around most fragments 3
Moderate presence of cells in cracks of implant and/or formation of
ﬁbrous tissue around fragments of implant
2
Minimal presence of cells within cracks of the implant (some cells present with or
without connective tissue formation)
1
Degradation Abundant degradation of implant with (almost) complete fragmentation 4
Marked degradation of implant with presence of several fragments 3
Moderate degradation of implant with cracks in implant and/or some fragments 2
Minimal degradation of implant, some minor dissolution on edges, cracks in
implant and/or small fragment present
1
FIGURE 1. Weight loss proﬁle of different groups after subcutaneous implantation for up to 12 weeks. Results are expressed as means 6 stand-
ard deviation with n ¼ 3 for each bar. (*) indicates a signiﬁcant difference (p < 0.05) between groups at the same time point. (**) indicates a sig-
niﬁcant difference (p < 0.05) between the same condition at different time points.
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implantation times, the degradation and the in situ formation
of pores will be greater than that obtained in the present
studies performed up to 12 weeks. Comparing all groups at
the same time point, chitosan scaffolds had the lowest weight
loss overall, but this was, as expected, slightly increased when
lysozyme was present. Chitosan/starch scaffolds with and
without CaP and in the presence or absence of lyzozyme (CS,
CaPCS þ lysozyme, and CaPCS, respectively) demonstrated
greater weight loss than chitosan scaffolds (CH, CaPCH, and
CaPCH þ lysozyme) after 6 and 12 weeks (Fig. 1).
Previous studies investigated the degradation of chitosan
scaffolds with and without CaP coating and in the presence
and absence of lysozyme at pH 5 to simulate the inﬂamma-
tory response.2 The weight loss in vitro was not as
pronounced as that observed in vivo. Similar to the in vivo
experiments described herein, in vitro CaP coated chitosan
scaffolds with incorporated lysozyme (CaPCH þ lysozyme)
had the highest weight loss.2 However, the complete dissolu-
tion of the CaP coatings was not observed in vivo, although
it was in vitro at pH 5, possibly indicating that the inﬂam-
matory response following implantation in vivo does not
achieve such a low pH or does not sustain this low pH for
as long as the previously performed in vitro study.2
This study also examined the effect of the addition of
starch into the chitosan phase compared with chitosan scaf-
folds alone. The presence of starch in addition to chitosan
seems to accelerate the degradation of scaffolds compared
to that of chitosan alone (Fig. 1). Starch is degraded by
a-amylase, an enzyme also present in the human body,
namely in the human blood.32 Starch granules with 5–
10 lm dimensions were homogeneously distributed
throughout the chitosan matrix enhancing hydrolysis by
FIGURE 2. Images of chitosan-based scaffolds obtained by l-CT: before implantation (week 0 -control) and after 3, 6, and 12 weeks of subcuta-
neous implantation. The scale bar is 1 mm and applies to all images.
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enzymes existing in vivo, namely lysozyme and a-amylase.1
The pore size and distribution in the scaffold are controlled
by the location of the ‘‘sacriﬁce’’ phase (starch), the degrada-
tion of which increases the microporosity by the release of
starch granules (small dots visible at high magniﬁcations in
Figure 4 for chitosan/starch scaffolds—CS, CaPCS, and
CaPCS þ lysozyme). These results are in agreement with
the weight loss data (Fig. 1).
l-CT analysis
The l-CT analysis performed on all experimental groups
showed an increase in scaffold porosity as a function of
implantation time (Fig. 2). At 3-weeks postimplantation,
degradation was observed in 3D images for chitosan-based
formulations compared with controls (Fig. 2). After 6 weeks,
results indicated increased degradation for all the materials.
The trend towards an accelerated increase in porosity/
degradation was observed for all conditions up to week 12
as can be observed in Figure 2. Nevertheless, analysis of the
3D images did not indicate a remarkable effect for the pres-
ence of lysozyme in chitosan scaffolds, but there did appear
to be enhanced degradation after 6 and 12 weeks when
lysozyme was incorporated in CaP chitosan/starch scaffolds
(Fig. 2). Furthermore, the CaP coating (dark grey) was
observed in 3D images at all time points for CaP coated
scaffolds, indicating the aforementioned lack of coating deg-
radation as was previously observed in vitro2 (Fig. 2).
According to Figure 3(A), all groups had an increase of
porosity after 3 weeks of implantation. However, no signiﬁ-
cant differences in porosity were found between groups at
the same time point with the exception of CaP chitosan/
starch scaffolds with incorporated lysozyme (CaPCS þ lyso-
zyme) after 6 weeks of implantation. This condition (CaPCS
þ lysozyme) presented signiﬁcant higher porosity (p <
0.05) compared with chitosan/starch scaffolds (CS) (43% 6
7% and 27% 6 4%, respectively). After 6 weeks of implan-
tation lysozyme seems to positively enhance the porosity, of
chitosan/starch scaffolds corroborating the weight loss
results (Fig. 1). After 3 weeks, no signiﬁcant differences
were found for all studied groups when compared with the
porosity of the corresponding control (nonimplanted, W0)
samples. However, after 6 weeks of implantation, porosity
FIGURE 3. Porosity (A) and pore interconnectivity (B) of chitosan-based scaffolds before implantation (week 0 -control) and as a function of im-
plantation time. Results are expressed as means 6 standard deviation with n ¼ 3 for each bar. (*) indicates a signiﬁcant difference (p < 0.05)
between groups at different time points compared with controls (0 days). (**) indicates a signiﬁcant difference (p < 0.05) between different
groups at the same time point.
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signiﬁcantly increased for chitosan (CH), chitosan/starch
(CS), and CaP chitosan/starch scaffolds with incorporated
lysozyme (CaPCS þ lysozyme) [Fig. 3(A)], relative to the
respective W0 controls. The same trend was observed after
12 weeks of implantation, showing signiﬁcantly higher
porosity for all scaffolds compared to that of control sam-
ples. These results indicate that all groups have the ability
to form pores in situ as a function of implantation time. All
groups presented a signiﬁcant increase in porosity over
time that was further enhanced by the presence of lyso-
zyme. In the absence of lysozyme, CS scaffolds presented an
increase of 22% of porosity over 12 weeks of implantation
(initial porosity of 10% 6 8% increased to 32% 6 10%),
while the porosity of CaPCS þ lysozyme scaffolds increased
FIGURE 4. Representative histological sections of scaffolds implanted subcutaneously and stained with H&E after 3, 6, and 12 weeks. The
images, showing the progressive degradation of materials accompanied by a progressive tissue ingrowth, are presented at 4 and 40 magniﬁ-
cation. The scale bars represent 500 lm and apply to all images. Chitosan-based scaffolds (M) appear in red. Pores (P) appear ﬁlled by cells (Ce)
in pink or blue. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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32% after only 6 weeks (initial porosity of 9% 6 5% and
43% 6 7% after 6 weeks). The degradation and conse-
quently the porosity is expected to be greater for longer
implantation times. The pore interconnectivity of chitosan
(CH) scaffolds signiﬁcantly increased with increased implan-
tation time when compared to the interconnectivity of con-
trol samples [Fig. 3(B)]. No signiﬁcant differences in pore
interconnectivity were observed between groups at the
same time point. After 12 weeks all groups demonstrated a
signiﬁcant increase in pore interconnectivity with the excep-
tion of chitosan/starch scaffolds and CaPCS þ lysozyme.
Lysozyme seems to have no effect on pore interconnectivity;
however, interconnectivity increased for all groups over
time with a range of values from 24–31% and 43–79%,
before and after 12 weeks implantation, respectively.
Microscopy analysis
Upon retrieval of the implants, no macroscopic signs of
infection were observed at the surgical sites. Furthermore,
no adverse tissue reactions (toxic effects) were observed
with light microscopy. Specimens for microscopy were
retrieved at 3, 6, and 12 weeks postimplantation. Polymer
and CaP coating degradation, cellular ingrowth within the
implants, as well as tissue response were assessed using
histological techniques. Remaining scaffolds were easily
identiﬁed after H&E staining, as chitosan and chitosan/
starch stained red, and cells stained blue and pink. In
Figure 4, CaP coatings are not easily identiﬁed (appear in
dark blue/black), but to speciﬁcally stain calcium, several
sections were stained with von Kossa (Fig. 6). For almost all
scaffold formulations, the formation of pores and the inﬁl-
tration of cells throughout the scaffolds (clearly visible at
high magniﬁcations) were evident, indicating material deg-
radation and interconnectivity of the pores (Fig. 4). Degra-
dation of scaffolds within the initially almost nonporous net-
work of chitosan or chitosan/starch is evident through the
presence of circular or irregular structures (pores) ﬁlled
with cells (Fig. 4). Furthermore, as a function of implanta-
tion time, scaffolds have changed their shape and size,
meaning that the scaffolds have been partially degraded and
resorbed (Fig. 4). The inﬁltration of cells as a function of
time is clearly visible [Fig. 5(A)] and occurred mainly when
lysozyme was present. The progression of in vivo degrada-
tion was also evident by the qualitative observation of the
formation of pores (Fig. 4). The increased scoring of degra-
dation, especially when lysozyme was present, corroborated
these data [Fig. 5(B)]. The degradation of scaffolds did not
elicit a severe inﬂammatory response. For the success of a
FIGURE 5. Results of histological scoring of: (A) cellular growth within the implants and (B) degradation after 3, 6, and 12 weeks of subcutane-
ous implantation. Data are presented as means 6 standard deviation for n ¼ 4–5. (*) indicates a signiﬁcant difference (p < 0.05) between groups
at the same time point.
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FIGURE 6. Representative light microscope images of the observed tissue responses at the implant interfaces. Chitosan/starch scaffolds (A–C)
and CaP chitosan/starch scaffolds with incorporated lysozyme (D-F) stained with H&E after 3 (A, D), 6 (B, E), and 12 weeks (C, F) after subcutane-
ous implantation. Yellow arrows correspond to collagen deposits; black arrows represent blood vessels; dashed black arrows indicate scaffold
fragments inside giant cells; G, giant cells; F, ﬁbroblasts. The images are presented at 20 magniﬁcation. The scale bar is 200 lm and applies to
all images. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 7. Representative images of van Gieson staining (A and C) and polarized light micrographs (B and D) of tissue surrounding chitosan
(A and B) and CaPCH with incorporated lysozyme scaffolds (C and D) after 6 weeks of implantation. The images are presented at 10magniﬁcation.
The scale bar is 200 lm and applies to all images. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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bone tissue engineering implant, the scaffold must have a
rate of degradation that corresponds to the rate of new
bone ingrowth. The present strategy of in situ pore forma-
tion seems to have the potential to allow for a gradual
transfer of mechanical support from the initial almost
nonporous material to the tissue as a function of pore
formation/scaffold degradation.
Biocompatibility is deﬁned as ‘‘the ability of a material
to perform with an appropriate host response in a speciﬁc
situation.’’33 The implantation of a biomaterial initiates a
sequence of events starting with an acute inﬂammatory
response and leading, in some cases, to a chronic inﬂamma-
tory response and/or granulation tissue development, a for-
eign body reaction and ﬁbrous capsule development.34,35 In
the literature, it is indicated that the intensity of the tissue
response may be modulated by the biodegradation process,
which in turn may be related with shape, porosity, surface
roughness changes, formation of particulates, and release of
degradation products.34
After 3 weeks of implantation, it was possible to observe
macrophages, small blood vessels, ﬁbroblasts, and some
collagen [Fig. 6(A,D)]. After 6 weeks, the proliferation of
ﬁbroblasts and collagen ﬁbrils become more abundant
[Figs. 6(B,E) and 7] as well as multinuclear (giant cells)
[Fig. 6(B,E)]. Collagen was visible even after 3 weeks [Fig. 6(A)]
although after 6 weeks collagen deposition was more
pronounced for all group conditions [Fig. 6(B,E)]. Collagen
deposition was further conﬁrmed by van Gieson staining
and polarized light microscopy (Fig. 7). Furthermore, newly
generated blood vessels were observed in the proximity of
the implants [Fig. 6(D)]. The vascularization already
observed in earlier times of implantation increased as the
a-SMA labeling shows the newly formed blood vessels
(Fig. 8). The density of vascularization increased as a func-
tion of implantation time (Fig. 8).
Foreign body reaction with granulation tissue is consid-
ered the normal wound healing response to implanted
biomaterials.35 Foreign body giant cells, implicated in the
biodegradation of polymeric biomaterials,35 were detected
after 3 and 6 weeks [Fig. 6(A,B,D,E)] and increased after 12
weeks of implantation [Fig. 6(C,F)]. The foreign body
reaction is composed of foreign body giant cells and the
components of granulation tissue, such as, macrophages,
ﬁbroblasts, and capillaries in varying amounts.35 The foreign
body reaction consisting mainly of macrophages and/or
foreign body giant cells may persist at the tissue-implant
interface for the lifetime of the implant.35 In the case of
biodegradable polymers, the foreign body reaction will in
general become persistent until ﬁnal degradation is
achieved.36 It was observed that the number of macro-
phages and giant cells increased as a function of time
(Fig. 6) to attempt to phagocytose the implanted materials.
FIGURE 8. Representative a-SMA immunostaining images of tissue surrounding CaPCH with incorporated lysozyme after 3 and 6 weeks (B and
C) and CaPCS after 12 weeks of implantation (D). Negative control (A). Arrows indicate blood vessels. The images are presented at 10 magniﬁ-
cation. The scale bar is 200 lm and applies to all images. [Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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The interface between material and surrounding tissue at
12 weeks consisted in ﬁbrin, macrophages and foreign body
giant cells [Fig. 6(F)]. At the same time point, most scaffold
formulations presented signs of degradation, as represented
in Figure 6(F) where small fragments of material have been
phagocytosed by giant cells. It was reported a similar
behavior of 6 months implanted poly(D,L-lactide-caprolac-
tone) with biomaterial particles engulfed inside giant cells.37
Degradation of these materials can also interfere with
wound healing. After 12 weeks healing tissue becomes
unorganized with an increase of inﬂammatory cells and this
can be attributed to degradation of the implanted materials,
mainly when lysozyme was present [Fig. 6(F)]. The persist-
ence of resident inﬂammatory cells may indicate that when
lysozyme is present, the materials are undergoing active
biodegradation. These materials did not induce a severe or
abnormal inﬂammatory reaction at all studied implantation
times. Although characterization of the speciﬁc types and
FIGURE 9. Representative light microscope images of chitosan-based sections stained with von Kossa after 3, 6, and 12 weeks of subcutaneous
implantation. The images are presented at 4 magniﬁcation. The scale bar is 500 lm and applies to all images. Chitosan-based scaffolds (M)
are stained in gray. Pores (P) are ﬁlled with cells (Ce) and appear in pink. CaP coatings (CaP) appear in black. [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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numbers of cells recruited to the constructs was beyond
the scope of the present study, such characterization in
future studies may elucidate the potential role of the CaP
coatings and the presence of the released lysozyme on
the overall inﬂammatory response of the host and the
potential consequent effects on mineral turnover and bone
deposition.
The principle of the biomimetic route is to immerse a
substrate into simulated body ﬂuid, favoring the nucleation
and growth of bone-like apatite under physiological condi-
tions of temperature and pH.38 When a bioactive material is
implanted, one of the ﬁrst events is an ionic exchange
between the CaP in contact with body ﬂuids.39 The dissolu-
tion leads to an increase of supersaturation at the surround-
ing area of the implant and afterwards to a precipitation
onto the substrate of a bone-like carbonate apatite struc-
ture.39–41 During resorption, the degradation products of
CaP coatings (calcium and phosphate ions) are naturally
metabolized and do not induce abnormal calcium and phos-
phate levels in urine, serum, or organs.42,43 The dissolution
of CaP coatings depends on the particle size, crystallo-
graphic features, density and the nature of the solution used
to make the coating (composition, pH, and tempera-
ture).43,44 These CaP coatings are partially amorphous and
quite stable at pH 7.4.2 Figure 9 shows von Kossa stained
sections with CaP coating on or within the implants. The
material is stained in gray, cells in pink, and CaP coating in
black. All sections, with the exception of the controls (with-
out CaP coatings), have black regions around or within the
implants, meaning that the CaP coating did not dissolve
completely. Signs of degradation of CaP coating were also
evident in Figure 9. However, the coatings did not disappear
in vivo but signiﬁcantly increased. These results are corro-
borated by 3D images obtained by l-CT (Fig. 2) and results
obtained by TGA (Fig. 10). It was also possible to investigate
the role of body ﬂuids without the inﬂuence of bone cells,
since these coated materials were tested subcutaneously in
rats. TGA allowed quantiﬁcation of the amount of mineral
present on scaffolds preimplantation and indicated an
increase in inorganic component with implantation time
and for all coated conditions (Fig. 10). Furthermore, the
amount of mineral signiﬁcantly increased after 6 weeks for
chitosan/starch scaffolds (CaPCS and CaPCS þ lysozyme).
The same trend was observed after 12 weeks for all groups
with a signiﬁcant increase in the mineral/inorganic compo-
nent compared to that detected before implantation. The
obtained results suggest a calciﬁcation/precipitation of the
coating by mineral ions contained in the surrounding body
ﬂuid. This phenomenon was also observed in previous stud-
ies developed by Barre`re et al.39 We can state that in in vivo
conditions the pH was mostly kept above 5 since the herein
studied biomimetic CaP coatings are soluble at and below
pH 5, as previously demonstrated.2 Some studies showed
improvement in the stability of the bone-bonding interface,
at late implantation times of nonsoluble and stable CaP
coated materials.45,46 von Kossa stained sections also
support the H&E results and histological scoring showing
pronounced implant degradation as a function of implanta-
tion time and inﬁltration of cells throughout the implants
(Figs. 5, 6, and 9).
CONCLUSIONS
In this study, the pore formation and in vivo degradation of
chitosan-based materials, as well as the tissue response to
the materials, were analyzed. The results demonstrated
weight loss and increased porosity of the materials in a rat
subcutaneous implantation model. Moreover, H&E staining
of the sections obtained at different time points showed
pores completely ﬁlled with cells, signifying that largely
solid scaffolds were able to degrade, form pores and conse-
quently be colonized by cells. Furthermore, l-CT results cor-
roborated these ﬁndings, showing that porosity signiﬁcantly
increased after 12 weeks of implantation, ranging from 22%
up to 32% for all conditions, and that the pores are inter-
connected. This strategy, using biodegradable naturally
occurring polymers such as chitosan and starch, seems to
maintain structural support throughout the implantation
period tested, with the formation of pores in situ allowing
for the penetration of cells into the implants with a normal
and mild inﬂammatory response by the host in a subcutane-
ous site. The gradual in situ pore forming ability of chito-
san-based scaffolds was clearly demonstrated conﬁrming
the concept in vivo. This approach for in situ pore formation
may have a lasting in bone tissue engineering by enabling
gradual introduction of porosity into a scaffold in vivo to
allow for tissue inﬁltration and load transfer to the tissue as
a function of implantation time.
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FIGURE 10. Quantiﬁcation of mineral/inorganic component of chito-
san-based scaffolds preimplantation and after 3, 6, and 12 weeks of
implantation determined by TGA analysis. Data are presented as
means 6 standard deviation for n ¼ 3. (*) indicates a signiﬁcant dif-
ference (p < 0.05) at different time points compared with the control
(0 weeks) for the same condition.
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